Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.

por Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Madhavi Tripathi, Nishikant Avinash Damle, Shamim Ahmed Shamim, Rakesh Kumar, Amlesh Seth, Chandrasekhar Bal
Publicado 2021